Table 2 Unadjusted hazard ratios for recurrence in relation to stromal ER and PR expression, allover and stratified by KRAS mutation status and sex, respectively

  ER-

118 (84)

1.00

40 (23)

1.00

34 (29)

1.00

0.078

  ER+

48 (36)

0.90 (0.61–1.33)

13 (10)

1.49 (0.71–3.15)

12 (8)

0.54 (0.24–1.19)

0.056^a

  p

0.587

0.294

0.127

  ER-

49 (32)

1.00

17 (9)

1.00

14 (10)

1.00

0.544

  ER+

35 (24)

0.97 (0.57–1.65)

8 (5)

1.33 (0.44–4.00)

8 (5)

0.84 (0.28–2.53)

0.425^a

  p

0.905

0.615

0.760

  ER-

69 (52)

1.00

23 (14)

1.00

20 (19)

1.00

0.025

  ER+

13 (12)

1.02 (0.54–1.92)

5 (5)

2.30 (0.78–6.78)

4 (3)

0.31 (0.08–1.11)

0.015^a

  p

0.951

0.131

0.072

  PR-

111 (77)

1.00

38 (21)

1.00

29 (26)

1.00

0.005

  PR+

49 (40)

1.25 (0.85–1.83)

12 (10)

2.07 (0.97–4.42)

17 (12)

0.50 (0.25–0.99)

0.008^a

  p

0.252

0.061

0.048^b

  PR-

52 (33)

1.00

18 (9)

1.00

12 (10)

1.00

0.005

  PR+

28 (22)

1.35 (0.79–2.33)

6 (5)

2.71 (0.89–8.26)

9 (5)

0.32 (0.11–0.97)

0.011^a

  p

0.276

0.080

0.043^b

  PR-

59 (44)

1.00

20 (12)

1.00

17 (16)

1.00

0.337

  PR+

21 (18)

1.20 (0.69–2.08)

6 (5)

1.64 (0.58–4.70)

8 (7)

0.84 (0.34–2.09)

0.249^a

  p

0.510

0.353

0.715